Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Labeling Is Critical As Bump From Compendia Listing Diminishes – Genentech

Executive Summary

Listing off-label uses in compendia may no longer provide the same bump in sales that would have been seen in the past, Genentech Exec VP - Commercial Operations Ian Clark said

You may also be interested in...



Avastin Experience Clarifies FDA Concerns With Cooperative Group Trials

FDA's concern with oncologic trials conducted by cooperative groups appears to be focused on the use of progression-free survival as an endpoint, according to Genentech Product Development President Susan Desmond-Hellman

Avastin Experience Clarifies FDA Concerns With Cooperative Group Trials

FDA's concern with oncologic trials conducted by cooperative groups appears to be focused on the use of progression-free survival as an endpoint, according to Genentech Product Development President Susan Desmond-Hellman

Roche Sees Avastin As Oncology Backbone, Will Focus On Combinations

Roche and Genentech's plans to establish Avastin (bevacizumab) as the "backbone" standard of care in oncology include a focus on combination use

Related Content

Latest News
UsernamePublicRestriction

Register

PS047388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel